Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env-V2

The RV144 trial demonstrated 31% vaccine efficacy (VE) at preventing HIV-1 infection1. Antibodies against the HIV-1 envelope variable loops 1 and 2 (V1/V2) domain correlated inversely with infection risk2. We hypothesized that vaccine-induced immune responses against V1/V2 would selectively impact,...

Full description

Bibliographic Details
Main Authors: Rolland, Morgane, Edlefsen, Paul T., Larsen, Brendan B., Tovanabutra, Sodsai, Sanders-Buell, Eric, Hertz, Tomer, deCamp, Allan C., Carrico, Chris, Menis, Sergey, Magaret, Craig A., Ahmed, Hasan, Juraska, Michal, Chen, Lennie, Konopa, Philip, Nariya, Snehal, Stoddard, Julia N., Wong, Kim, Zhao, Hong, Deng, Wenjie, Maust, Brandon S., Bose, Meera, Howell, Shana, Bates, Adam, Lazzaro, Michelle, O'Sullivan, Annemarie, Lei, Esther, Bradfield, Andrea, Ibitamuno, Grace, Assawadarachai, Vatcharain, O'Connell, Robert J., deSouza, Mark S., Nitayaphan, Sorachai, Rerks-Ngarm, Supachai, Robb, Merlin L., McLellan, Jason S., Georgiev, Ivelin, Kwong, Peter D., Carlson, Jonathan M., Michael, Nelson L., Schief, William R., Gilbert, Peter B., Mullins, James I., Kim, Jerome H.
Format: Online
Language:English
Published: 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551291/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551291/

Similar Items